Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Clear Cell Renal Cell Carcinoma
Related studies linked through entity extraction aliases.
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
- Status
- RECRUITING
- Phase
- PHASE2
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
- Status
- RECRUITING
- Phase
- PHASE2
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
- Status
- RECRUITING
- Phase
- PHASE2
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- Status
- RECRUITING
- Phase
- PHASE2
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
- Status
- SUSPENDED
- Phase
- PHASE2
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Status
- RECRUITING
- Phase
- PHASE1
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
- Status
- RECRUITING
- Phase
- PHASE3